stockportfolio.pro
Stocks / HALO vs UHS
HALO vs UHS
Halozyme Therapeutics, Inc. and Universal Health Services, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Halozyme Therapeutics, Inc. (HALO) | Universal Health Services, Inc. (UHS) | |
|---|---|---|
| Market cap | $8.4B | $8.8B |
| Revenue (latest FY) | $1.40B | $17.36B |
| Net income (latest FY) | $316.89M | $1.49B |
| Revenue growth (5y CAGR) | 39.2% | 8.5% |
| Net margin | 22.7% | 8.6% |
| Return on equity | 649.2% | 20.5% |
| P/E ratio | 24.9 | 6.1 |
| Dividend yield | — | 0.5% |
| Profitable years (of last 10) | 7 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HALO — free Open UHS — freeFrequently asked questions
Which is bigger, HALO or UHS?
Universal Health Services, Inc. is larger by market capitalization — $8.8B versus $8.4B.
Which grows faster, HALO or UHS?
Over the last five fiscal years, Halozyme Therapeutics, Inc. grew revenue faster — 39.2%/yr versus 8.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.